About Mérieux Equity Partners

• Founded: 2008

• Headquarters: Lyon, France

• Strategy: Mid-market healthcare buyout, Europe

• Thesis: Backs European healthcare businesses positioned to benefit from structural growth drivers in biopharma, medtech, and specialty care delivery, with a focus on operational partnerships that accelerate development and international expansion.

• Track record: Fund IV raised €380m in 2019; Fund III closed at €265m in 2015

• Leadership: Founded by Philippe Mérieux and Hervé Lévesque

Mérieux Equity Partners closed its fifth fund's first close at €335m, reaching 56% of the €600m target just four months after launch. The vehicle follows Fund IV's €380m close in 2019 and continues the firm's focus on European healthcare buyouts. The first close was oversubscribed relative to initial LP expectations, reflecting sustained appetite for specialist healthcare strategies in the current market.

The four-month timeline to first close positions Fund V among the faster healthcare fund raises in the current cycle. That pace stands out against the 14-month median first-close timeline for European buyout funds launched in 2024, per PitchBook data. The firm's track record with Fund IV — which deployed into 12 platform investments over a five-year period — likely supported the momentum, as did the sector's defensiveness during recent volatility.

The €600m target represents a 58% step-up from Fund IV, raising questions about deployment capacity in a market where quality healthcare assets at mid-market scale are increasingly competed for by both specialist funds and crossover growth investors. With the first close complete, the firm's deployment timeline over the next 18 months will test whether the larger fund size translates to portfolio construction at the same pace as its predecessor, or whether heightened competition pushes the firm toward larger deals or longer hold periods.

Source: AltAssets